cabozantinib

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Medullary Thyroid Cancer

Conditions

Medullary Thyroid Cancer

Trial Timeline

— → —

NCT ID

NCT01683110

About cabozantinib

cabozantinib is a pre-clinical stage product being developed by Exelixis for Medullary Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01683110. Target conditions include Medullary Thyroid Cancer.

What happened to similar drugs?

1 of 4 similar drugs in Medullary Thyroid Cancer were approved

Approved (1) Terminated (1) Active (2)

✅Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsuleExelixisApproved

🔄Selpercatinib + Cabozantinib + VandetanibEli LillyPhase 3

❌Pralsetinib + Cabozantinib + VandetanibRochePhase 3

🔄VandetanibSanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01683110	Pre-clinical	Completed	—	—	Medullary Thyroid Cancer
NCT06132945	Phase 1	Active	Nov 10, 2023	Nov 1, 2027	Metastatic Renal Cell Carcinoma
NCT06156410	Phase 1	Recruiting	Oct 24, 2023	Nov 1, 2028	Ewing Sarcoma
NCT05613894	Phase 1	Recruiting	Jul 14, 2023	May 1, 2028	Metastatic Castration-resistant Prostate Cancer
NCT05135975	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2029	Neuroblastoma
NCT05425004	Phase 2	Recruiting	Jun 1, 2022	May 1, 2028	Meningioma
NCT04497038	Phase 1/2	Terminated	Aug 6, 2021	May 2, 2023	Advanced Adult Hepatocellular Carcinoma
NCT04876456	Phase 2	Active	Jun 10, 2021	Jan 1, 2027	Germ Cell Tumor
NCT04631744	Phase 2	Completed	Mar 3, 2021	Nov 9, 2025	Prostate Cancer
NCT04412629	Phase 2	Active	Nov 24, 2020	Sep 30, 2026	High Grade Neuroendocrine Neoplasms
NCT03964337	Phase 2	Terminated	Mar 17, 2020	Jun 4, 2021	Prostate Cancer
NCT04022343	Phase 2	Active	Aug 6, 2019	Mar 1, 2026	Clear Cell Renal Cell Carcinoma
NCT02132598	Phase 2	Terminated	Dec 1, 2015	Aug 9, 2019	Non Small Cell Lung Cancer (NSCLC)
NCT02036476	Phase 2	Terminated	Feb 1, 2014	Jul 1, 2016	Merkel Cell Carcinoma
NCT01961765	Phase 1	Completed	Nov 1, 2013	Jan 1, 2017	Relapsed Acute Myeloid Leukemia
NCT01954745	Phase 2	Completed	Sep 1, 2013	Jun 1, 2016	Bile Duct Cancer
NCT01761773	Phase 1	Completed	Dec 1, 2012	Jul 1, 2014	Healthy
NCT01639508	Phase 2	Recruiting	Jul 1, 2012	Jul 1, 2026	Non-Small Cell Lung Cancer
NCT01428219	Phase 2	Terminated	Feb 1, 2012	Sep 1, 2015	Prostate Cancer Metastatic
NCT01493869	Phase 1	Completed	Sep 1, 2011	Aug 1, 2014	Healthy

Competing Products

9 competing products in Medullary Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
Selpercatinib + Cabozantinib + Vandetanib	Eli Lilly	Phase 3	44
Selpercatinib	Eli Lilly	Phase 1/2	36
Pralsetinib + Cabozantinib + Vandetanib	Roche	Phase 3	32
• TF2 and 68 Ga-IMP-288	Gilead Sciences	Phase 1/2	32
Caprelsa	Sanofi	Pre-clinical	26
Vandetanib 300mg	Sanofi	Phase 1/2	32
Vandetanib	Sanofi	Phase 3	40
vandetanib + omeprazole + ranitidine	Sanofi	Phase 1	29
Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule	Exelixis	Approved	44